Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Cofactor Mimics as Selective Inhibitors of NAD-dependent Inosine Monophospate Dehydrogenase (IMPDH) - the Major Therapeutic Target

Author(s): Krzysztof W. Pankiewicz, Steven E. Patterson, Paul L. Black, Hiremagalur N. Jayaram, Dipesh Risal, Barry M. Goldstein, Lieven J. Stuyver and Raymond F. Schinazi

Volume 11 , Issue 7 , 2004

Page: [887 - 900] Pages: 14

DOI: 10.2174/0929867043455648

Price: $65

Abstract

IMP dehydrogenase, the key enzyme in de novo synthesis of purine nucleotides, is an important therapeutic target. Three inhibitors of IMP dehydrogenase reached the market; ribavirin (Rebetol) a broadspectrum antiviral agent, which in combination with interferon-α is now used for treatment of hepatitis C virus infections, mizoribine (Bredinin) and mycophenolic mofetil (CellCept) have been introduced as immunosuppressants. Numerous novel inhibitors are under development. This review describes recent progress in the development of new drugs based on inhibition of IMP dehydrogenase.

Keywords: inosine monophospate dehydrogenase, imp dehydrogenase, purine nucleotides, mycophenolic mofetil


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy